Delaware State Sen. Sarah McBride, who is favored to become the first transgender member of Congress after winning the Democratic primary this week, received a congratulatory call on Wednesday from a powerful friend and ally: President Joe Biden.

The president shared details about their conversation with the Washington Blade during an exclusive interview in the Oval Office on Thursday, which will be available to read online early next week.

“I called her and I said, ‘Sarah,’ I said, ‘Beau’s looking down from heaven, congratulating you,'” Biden said, referring to his late son, who had served as attorney general of Delaware before his death from cancer in 2015.

McBride had worked on Beau Biden’s campaign in 2006 and on his reelection campaign in 2010. Two years later, when she came out as transgender, the AG called to say, “I’m so proud of you. I love you, and you’re still a part of the Biden family.”

The president told the Blade that McBride welled with emotion — “she started to fill up” — as she responded that the “‘only reason I’m here is because of Beau. He had confidence in me.’”

When the two worked together, “[Beau] was getting the hell kicked out” of him because “he hired her,” Biden said, but “now she’s going to be the next congresswoman, the next congresswoman from Delaware.”

Later, when asked how he will remain involved in the struggle for LGBTQ rights after leaving office, the president again mentioned McBride. “Delaware used to be a pretty conservative state, and now we’re going to have — Sarah is going to be, I pray to God, a congresswoman.”

The U.S. pharmaceutical company Gilead Sciences announced on Sept. 12 the findings of its most recent Phase 3 clinical trial for its twice-yearly injectable HIV prevention drug Lenacapavir show the drug is highly effective in preventing HIV infections, even more so than the current HIV prevention or PrEP drugs in the form of a pill taken once a day.

There were just two cases of someone testing HIV positive among 2,180 participants in the drug study for the twice-yearly Lenacapavir, amounting to a 99.9 percent rate of effectiveness, the Gilead announcement says.

The announcement says the trial reached out to individuals considered at risk for HIV, including “cisgender men, transgender men, transgender women, and gender non-binary individuals in Argentina, Brazil, Mexico, Peru, South Africa, Thailand and the United States who have sex with partners assigned male at birth.”

“With such remarkable outcomes across two Phase 3 studies, Lenacapavir has demonstrated the potential to transform the prevention of HIV and help to end the epidemic,” Daniel O’Day, chair and CEO of Gilead Sciences said in the announcement.

 “Now that we have a comprehensive dataset across multiple study populations, Gilead will work urgently with regulatory, government, public health, and community partners to ensure that, if approved, we can deliver twice-yearly Lenacapavir for PrEP worldwide for all those who want or need it,” he said.

Carl Schmid, executive director of the D.C.-based HIV+ Hepatitis Policy Institute, called Lenacapavir a “miracle drug” based on the latest studies, saying the optimistic findings pave the way for the potential approval of the drug by the U.S. Food and Drug Administration in 2025.

“The goal now must be to ensure that people who have a reason to be on PrEP are able to access this miracle drug,” Schmid said in a Sept. 12 press release. “Thanks to the ACA [U.S. Affordable Care Act], insurers must cover PrEP without cost sharing as a preventive service,” he said.

“Insurers should not be given the choice to cover just daily oral PrEP, particularly given these remarkable results,” Schmid said in the release. “The Biden-Harris administration should immediately make that clear. To date, they have yet to do that for the first long-acting PrEP drug that new plans must cover,” he said.

Schmid, through the HIV+ Hepatitis Policy Institute, has helped to put together a coalition of national and local HIV/AIDS organizations advocating for full coverage of HIV treatment and prevention medication by health insurance companies.

A statement by Gilead says that if approved by regulatory agencies, “Lenacapavir for PrEP would be the first and only twice-yearly HIV prevention choice for people who need or want PrEP. The approval could transform the HIV prevention landscape for multiple populations in regions around the world and help end the epidemic.”

Uruguay’s LGBTQ community finds itself in a moment of strategic reflection and coordinated action in this crucial election year.

With presidential elections on the horizon, diverse voices inside and outside the Uruguayan political arena are advocating for representation. They are also working to confront the challenges facing the country’s queer population in obtaining positions in Congress. 

Uruguay is one of the first countries in Latin America to implement legislation and public policies to improve the quality of life of LGBTQ people. Uruguay, in fact, is considered one of the safest countries in the world for queer tourists.

In recent years, however, LGBTQ people been underrepresented in Congress and other political spaces. And activists see the Oct. 27 election as an opportunity to gain space. 

Diego Sempol, a renowned Uruguayan political scientist, told the Washington Blade that LGBTQ participation in national politics is important. 

“It is crucial for the LGBTQ+ community to hold positions in Congress to make their issues visible,” he said. “This not only drives more inclusive legislative advances, but also challenges existing social prejudices.” 

“I think it would seem important to run for a position in Congress or in the Senate because it would contribute to make the LGBTIQ+ population visible at the political level, which is very good because it is still a great centrality for a large part of the population and therefore achieving voting places, important places voted for, confirms that there is an advance or a setback in social prejudices about dissident gender identities,” added Sempol.

Daniela Buquet, a spokesperson for Colectivo Ovejas Negras, a Uruguayan advocacy group, explained how the LGBTQ movement is approaching this electoral cycle.

“We find ourselves in a context where the major political discussions are still centered on traditional figures, mostly white, upper-class cis males,” said Buquet. “However, we are moving forward strategically, strengthening our demands as the campaign progresses.” 

The recent primaries showed a political dynamic marked by established figures and discussions that do not always address the needs of social movements. Buquey stressed “LGBTQ+ candidacies are scarce in high-level positions, but we see progress at lower levels of the legislature, where congressmen and congresswomen are beginning to incorporate our concerns.” 

The electoral panorama reflects a clear division between the main parties, the Frente Amplio and the Partido Nacional, while parties such as Cabildo Abierto, known for its conservative and homophobic stance, are also part of the scenario. 

“We have seen attempts of setbacks by sectors such as Cabildo Abierto, but also resistance and social mobilization that have prevented significant negative changes.” said Buquet. 

The current government has faced criticism for its lack of compliance and progress on critical issues for the LGBTQ community. 

“The comprehensive law for trans people is still not fully implemented, and educational and health programs remain insufficient,” Buquet noted. 

The debate on inclusion and sexual diversity in Uruguay is not limited to the legislative arena, but encompasses the effective implementation of inclusive social and educational policies. LGBTQ activists expect the next government to take concrete steps to guarantee rights and improve the quality of life of all citizens, regardless of their sexual orientation or gender identity. 

With the diversity march scheduled for this month, LGBTQ social organizations and collectives will continue to push for more equitable representation and effective public policies. The challenge is clear: “Transform visibility into tangible political action that benefits all of Uruguayan society.”